If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
253
results.
Updated on
07/05/2026 [07:05:00]
Results 100 to 125 of 253
Absstract of: WO2026090266A2
The present disclosure relates, in one aspect, to ionizable lipid prodrug compounds of formula (I). In another aspect, the disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I). In another aspect, the disclosure provides methods of the LNPs of the disclosure for splenic delivery of therapeutic cargo.
Absstract of: WO2026090175A2
The present disclosure relates, in one aspect, to propargyl amino-ionizable lipid compounds of formula (I), and methods of preparing the same. In another aspect, the disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I) or (III). In another aspect, the LNPs of the disclosure are useful for gene editing applications. In another aspect, the LNPs of the disclosure are useful for splenic delivery of therapeutic cargo.
Absstract of: US20260115146A1
A method for encapsulating a low-solubility phytochemical into a water-soluble nano-complex is presented. The method involves creating a mixture of one or more proteins and a solvent, followed by adjusting the pH to an alkaline condition using an alkaline compound. Zein protein and a low-solubility phytochemical are sequentially added, with the proteins unfolding under alkaline conditions to capture the phytochemical through hydrophobic interactions. The pH is then adjusted to a neutral range using an acidic compound, refolding the zein protein and forming a nano-complex. The solution is dried to produce a dry powder, where the resulting nano-complex has a particle size of less than 1 μm, with the proteins encapsulating the phytochemical.
Absstract of: US20260115228A1
0000 Provided herein are RNA sequences encoding a chimeric antigen receptor (CAR) comprising a CD19 antigen binding molecule, along with related compositions and methods. In some embodiments, circular RNAs encoding the CD19 binding molecule or CD19 CAR, along with related compositions, methods, and precursors, are described herein. In some embodiments, these compositions comprise a transfer vehicle, e.g., comprising an ionizable lipid described herein.
Absstract of: US20260115156A1
0000 Provided is an injectable composition including a compound configured to form nanoparticles, an anesthetic agent, and a hyaluronic acid hydrogel. According to the present disclosure, the injectable composition is injected in a liquid formulation and gelated in the body to prevent rapid decomposition, sustained-release the anesthetic agent for a long period of time, and locally remain in the body for a long period of time. In addition, the injectable composition may provide a long-term, sustained pain relief effect through the stable sustained-release of lidocaine.
Absstract of: US20260115145A1
0000 A method for enhancing drug solubility and preparing a drug composite material with enhanced solubility, comprising: S1,raw material preparation: preparing a colloidal suspension of silicon dioxide in water, including silicon dioxide nanoparticles with diameters ranging from 2 to 100 nm; S2, preparation of high-density silanol group surface material: rapidly evaporating the solvent from the silicon dioxide colloidal suspension by controlling temperature and pressure, thereby retaining an ultra-high density of silanol groups on the surface, enhancing the surface's affinity for drug molecules and water, and forming a porous structure to increase the specific surface area; S3, drug loading: mixing the active drug component with the high silanol group surface material, and load the drug molecules onto the material using a drug loading process. The method can significantly enhance the drug's solubility, potentially by two to three orders of magnitude.
Absstract of: WO2026087434A1
The present invention relates to a pharmaceutical composition comprising lipid nanoparticles (LNPs) comprising an mRNA for use in treating or preventing a cardiac disease or condition in a subject in need thereof, wherein, following administration to the subject, a polypeptide encoded by the mRNA is transiently expressed by liver cells and secreted into the blood of the subject, wherein the polypeptide exerts a therapeutic effect on the heart to treat or prevent the disease or condition. The present invention also provides LNPs comprising an mRNA encoding a cardiotherapeutic polypeptide and an ionisable lipid selected from ALC-0315, SM-102, or DLin-MC3-DMA or analogues thereof, particularly where the mRNA encodes Chrdl1, Fam3b, Fam3c, Mdk, pleiotrophin, HtrA1, Nhlrc3, or Rln-1 polypeptide. The present invention also provides kits for producing said LNPs, and a pharmaceutical composition or unit dose composition comprising said LNPs.
Absstract of: US20260117230A1
0000 Provided herein are nanoparticles comprising up to two miRNAs or miRNA zippers and up to two siRNAs for inhibiting up to four target nucleic acids. Template DNA sequences and methods for preparing the nanoparticles are also described. Also provided are methods for using sequence specific nanoparticles to treat various disorders.
Absstract of: WO2026090423A1
The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.
Absstract of: WO2026087624A1
The invention relates to a composition for use in the treatment or prevention of one or more unwanted radiation effects in a subject, wherein the one or more unwanted radiation effects are caused by the use of one or more radioactive drugs or external ionizing radiation and wherein the composition comprises silicon particles.
Absstract of: WO2026090544A1
An engineered transcriptional modulator (ETM) comprising: (a) at least one epigenetic effector domain; operably linked to (b) an endonuclease.
Absstract of: WO2026090113A1
The present invention provides methods for modifying a donor organ, e.g., liver, or a portion thereof. The methods comprise contacting the donor liver with lipid nanoparticles comprising RNA. Compositions of lipid nanoparticles comprising RNA are also provided. The disclosed LNPs may comprise an siRNA, e.g., targeting tissue plasminogen activator (tPA) or plasminogen activator inhibitor 1 (PAI-1). The LNPs may comprise an mRNA encoding a protein, e.g., Nuclear Factor-erythroid factor 2-related factor 2 (NRF2) or thrombomodulin.
Absstract of: US20260116928A1
The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.
Absstract of: US20260115144A1
Provided herein are terpenoid- and cannabinoid-encapsulating PLGA nanoparticles and pharmaceutical compositions comprising the nanoparticles. Further provided are methods of making and using the terpenoid- and cannabinoid-encapsulating PLGA nanoparticles for therapeutic purposes.
Absstract of: AU2026202687A1
The present invention is based, in part, on the identification of compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof. pr p r
Absstract of: WO2026090554A1
A method of preserving a nucleic acid, comprising: perturbing a composition comprising (a) the nucleic acid and (b) a water-miscible ionic liquid that includes (i) a positively-charged tertiary amine and (ii) a negatively-charged fatty acid or fatty alcohol, the perturbing causing formation of a nucleic acid-rich hydrophobic deep eutectic solution (hDES) in which the tertiary amine and the at least one of a fatty acid and a fatty alcohol are uncharged and associate via hydrogen bonding, and the nucleic acid-rich hDES being biocompatible. A preserved nucleic acid composition, comprising: a biocompatible hDES phase comprising (i) a nucleic acid, (ii) an uncharged tertiary amine, and (iii) and at least one of an uncharged fatty acid and an uncharged fatty alcohol, the uncharged tertiary amine and the at least one of an uncharged fatty acid and an uncharged fatty alcohol being associated with one another via hydrogen bonding.
Absstract of: WO2026090240A1
Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.
Absstract of: WO2026090457A1
This disclosure relates to methods and compositions for inhibiting expression and/or activity levels of nuclear receptor corepressor 1 (NC0R1) and/or myostatin (MSTN) to treat various diseases or disorders.
Absstract of: WO2026086071A1
The present invention belongs to the field of biotechnology. Provided are a circular IL-10 mRNA nano-preparation, and a preparation method therefor and the use thereof. The circular IL-10 mRNA nano-preparation is prepared by means of the following method: 1, synthesizing a chemically modified circular IL-10 mRNA in vitro; and 2, preparing, by means of self-assembly, a circular IL-10 mRNA nano-preparation that can be delivered in vivo. The circular IL-10 mRNA inhibits injury of articular cartilage by means of regulating immune cells in the synovial membrane of an articular cavity, thereby achieving the effect of treating inflammatory joint diseases.
Absstract of: US20260115251A1
The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.
Absstract of: US20260115310A1
0000 The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.
Absstract of: US20260115221A1
Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.
Absstract of: WO2026085904A1
A method for improving drug solubility and a drug composite material having improved solubility. The method comprises preparing a silica colloidal suspension from silica nanoparticles having a diameter between 2 nm and 100 nm; rapidly evaporating a solvent by means of controlling the temperature and pressure, so as to obtain a porous surface material with ultra-high density silanol groups retained on the surface; and loading drug molecules. By controlling the size of nanoparticles and the density of silanol groups, drug molecules can be effectively adsorbed under anhydrous conditions, and rapidly desorbed and released in an aqueous environment.
Absstract of: US20260116845A1
The present disclosure relates to cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of using and delivering the described lipids and lipid-containing particles.
Nº publicación: JP2026513706A 30/04/2026
Applicant:
カンシノ（シャンハイ）バイオロジカルリサーチカンパニーリミテッド
Absstract of: CN118852306A
The invention provides a steroid-cationic lipid compound with a structure as shown in a formula (I) and application of the steroid-cationic lipid compound, and the steroid-cationic lipid compound can be used for preparing lipid nanoparticles (LNPs) for delivering therapeutic agents and/or prophylactic agents. The LNP prepared from the steroid-cationic lipid compound disclosed by the invention has better stability and transfection efficiency. The LNP is used for delivering nucleic acid such as mRNA, bioactive substances can be efficiently and stably delivered to target cells or organs, and meanwhile, the LNP has high stability, can be used for lyophilized preparation development of mRNA and can also be used for aerosol inhalation administration of mRNA. High specific antibody response can be caused in an experimental animal body, and the compound has better safety. # imgabs0 #
BOPI
Electronic site
